Ileadbms

.

Creating Better Therapies for a Better Tomorrow iLeadBMS

At iLeadBMS, we are building a pipeline of innovative drugs to address the huge unmet needs in various therapeutic areas including oncology, fibrosis, neurodegeneration, and autoimmune diseases. Our core competencies are as follows:

R&D Strategy : Multiple, simultaneous targeting of key drivers of diseases to create highly de-risked molecules with ideal properties for clinical use:
Proven Track Record : Team of discovery experts with great depth of knowledge and experience in molecular design and medicinal chemistry [10+ discovery programs where 3 of these has advanced to clinical stage: (1) FXR agonist for MASH – Out-licensed to Yunovia, currently in phase 1, (2) A1A2a agonist for Parkinson’s disease – Out-licensed to Yunovia, currently in phase 1, (3) Venadaparib for gastric and breast cancer – Our-licensed to Idience, currently in phase 2]
Global Collaboration for Development Active collaborations with various partners around the globe to maximize the development success rates

Pipeline

iLeadBMS is innovative research-intensive pharma company with a robust globally competitive R&D pipeline

Autoimmune and Fibrotic Diseases

ACKR3 Ago-PAM for Autoimmune and Fibrotic Diseases
iLeadBMS is developing a first-in-class, orally available small molecule agonist and positive allosteric modulator (PAM) for ACKR3 (formerly CXCR7), atypical chemokine receptor 3 which is involved in inflammation and fibrosis in various organs such as the heart, lungs, liver, and skin. IL2112 is unique in that as a first-in-class ACKR3 Ago-PAM molecule, it offers triple mechanism of action which is highly advantageous for treating chronic diseases in the field of autoimmune and fibrosis where either standard therapies are lacking or suboptimal.
IL2112 has consistently demonstrated strong efficacy signal across several different in vivo efficacy models related to autoimmune (RA, IBD, MS, PAH) and fibrosis (lung, liver, kidney, cardiac, and skin fibrosis) models. Based on the accumulated preclinical data thus far, it is anticipated that IL2112 will have a significantly improved efficacy and safety profile over existing standard of care therapies.

Oncology

(1) Cyclin-K Degrader for Solid Tumors
iLeadBMS is developing a potentially first-in-class, orally available small molecule Cyclin-K degrader for various solid tumors including gastric, breast and colorectal cancers. Our compound acts as a Cyclin-K molecular glue, a highly promising type of Targeted Protein Degrader (TPD) and, has demonstrated a potent growth inhibition in various animal models including the HER2 negative gastric cancer and TNBC models. Based on the currently available data, it is anticipated that our Cyclin-K degrader has a potential to be developed as an intermittent oral monotherapy for many difficult solid tumors including those without identifiable drivers.

(2) SOS1 Inhibitor for RAS Driven Cancers
iLeadBMS is developing a potentially best-in-class, orally available small molecule SOS1 inhibitor for any RAS driven cancers. Our SOS1 inhibitor has a broad activity profile against various KRAS/RAS alleles including KRAS G12C, G12D, G12V and G13C. While our compound has demonstrated clear efficacy in animal models as a monotherapy, there was significant synergistic efficacy when combined with a KRAS inhibitor. Based on these promising preliminary results, it is anticipated that our SOS1 inhibitor can be developed as a powerful combination agent of choice for a broad type of KRAS inhibitors including both selective and the pan types.

Neurodegenerative Disease

CXCR7 Agonist for Neurodegenerative Diseases
iLeadBMS is developing a first-in-class, orally available small molecule chemokine agonist which upregulates the chemokine receptor 7 (CXCR7), This is a different CXCR7 agonist compound from the fibrosis program as we have identified a compound with an excellent B/P ratio (> 1) making it suitable for application in various neurodegenerative diseases. Our compound has demonstrated enhanced clinical behavior scores and reduced demyelination compared to the vehicle group in a mice MS model and additional neurodegeneration animal models are either ongoing or being planned.

.

Creating Better Therapies for a Better Tomorrow iLeadBMS

At iLeadBMS, we are building a pipeline of innovative drugs to address the huge unmet needs in various therapeutic areas including oncology, fibrosis, neurodegeneration, and autoimmune diseases. Our core competencies are as follows:

Pipeline

Autoimmune and Fibrotic Diseases

Oncology

Neurodegenerative Disease

NEWS & EVENT